<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00246805</url>
  </required_header>
  <id_info>
    <org_study_id>RARE-PEARL</org_study_id>
    <nct_id>NCT00246805</nct_id>
  </id_info>
  <brief_title>Heart Rate Regularization in Patients With Permanent Atrial Fibrillation Post Marketing Study</brief_title>
  <acronym>RARE-PEARL</acronym>
  <official_title>Post Marketing Study on Heart Rate Regularization in Patients With Permanent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic BRC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic BRC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor heart rate regularization in patients with permanent
      atrial fibrillation and standard indication for single chamber rate adaptive pacing VVI(R).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RARE PEARL is a multicenter prospective, randomized, double-blinded, crossover study.

      Prior entering the study the patient should be informed and should give his written consent.
      Besides he/she should meet all selection criteria. The Investigator has to check that all
      selection criteria are satisfied. Then the patient undergoes pacemaker implantation,
      receiving a pacemaker model C20 SSIR or T20 SSIR (or later). The ventricular lead must be
      bipolar independently of the manufacturer.

      After pacemaker implantation, a 45 days Stabilization Period is necessary to stabilize leads
      and drug therapy.

      At the end of the stabilization period the patient is randomized to have VRS algorithm
      switched either ON or OFF. The 1° Study Phase ends after 2 months. Then a cross-over takes
      place: VRS algorithm is switched respectively OFF or ON and the 2° Study Phase is started.
      Also the 2° Study Phase ends after 2 months.

      The randomization will be centralized: randomization lists will be generated and managed by
      the sponsor. Because the patients will undergo a QoL questionnaire at each crossover phase,
      they will have to be blinded about the status of their VRS setting. Similarly, also the
      co-investigators administering the QoL questionnaires have to be blinded about the status of
      VRS setting. Only the principal investigator knows if the VRS algorithm is ON or OFF. The
      principal investigator will be instructed not to inform the patient and the co-investigators
      administering QoL questionnaire about the setting until after the end of the study.

      The co-investigator(s) responsible for QoL questionnaire should not perform the patient
      follow-up at 1° and 2° Study Phase, otherwise the patient is automatically excluded from the
      study.

      After the cross-over period (2 + 2 months) a Free Therapy Phase (3° Phase) starts. Device
      settings and drug therapy are left to the physician's discretion.

      One year after implantation a final follow-up is scheduled. The study ends and the pacemaker
      can be programmed according to the physician's discretion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE)</measure>
    <time_frame>June 2009</time_frame>
    <description>Evaluation of patient preference concerning the programming of a specific algorithm for automatic Ventricular Rate Stabilization (VRS): Algorithm ON vs. OFF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Rate Irregularity Indicators and Patient's Symptoms</measure>
    <time_frame>January 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Should Undergo Atrioventricular Nodal (AVN) Ablation</measure>
    <time_frame>January 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Should Undergo Drug Therapy in Combination With Pacing to Stabilize Heart Rate</measure>
    <time_frame>January 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential Discomforts of Pacing Algorithm for Heart Rate Stabilization</measure>
    <time_frame>January 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Permanent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>1. VRS ON</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS) ON or OFF.
This arm (1) is randomized to Function Ventricular Rate Stabilization ON.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. VRS OFF</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with permanent atrial fibrillation implanted with VVI(R) pacemaker Vitatron model C20 SSIR or T20 SSIR were randomized to Function Ventricular Rate Stabilization (VRS)ON or OFF.
This arm (2) is randomized to Function Ventricular Rate Stabilization OFF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vitatron pacemaker C20 SSIR or T20 SSIR models</intervention_name>
    <description>VRS: special function that automatically adapts pacing rate to regularize cardiac cycles</description>
    <arm_group_label>1. VRS ON</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has signed informed consent form

          -  Patient with permanent atrial fibrillation, standard indication for VVI(R) pacing, and
             at least 1 episode of rate irregularity in the last month

          -  New York Heart Association (NYHA) Class I, II, III

          -  Patient is able to comply with follow-up times and will comply with the protocol

          -  &gt; 18 years of age

        Exclusion Criteria:

          -  Paroxysmal atrial fibrillation

          -  NYHA Class IV

          -  Left ventricular ejection fraction (LVEF) &lt; 35

          -  Patients with unstable angina

          -  Patients who have experienced an acute myocardial infarction or received coronary
             artery revascularization (CABG), or coronary angioplasty (PTCA) within 3 months prior
             to enrolment

          -  Patient candidate for cardiac surgery, or coronary angioplasty (PTCA)

          -  Patients who experienced a cardiovascular accident (CVA) or transient ischemic attack
             (TIA) with permanent disability

          -  Life expectancy &lt; 12 months due to other medical conditions

          -  Pregnancy

          -  The patient is enrolled in any concurrent (drug and/or device) study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Corbucci, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Vitatron Medical Italia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eraldo Occhetta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Maggiore della Misericordia - Novara</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianfranco Mazzocca, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale di Cecina (LI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Ospedale Civile</name>
      <address>
        <city>Livorno</city>
        <state>LI</state>
        <zip>57100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - ospedale Civile</name>
      <address>
        <city>Rieti</city>
        <state>RI</state>
        <zip>02100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Ospedale Civile</name>
      <address>
        <city>Acqui Terme</city>
        <zip>15011</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Az. Ospedaliera Umberto I</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - USL 8</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia- Ospedale di Cecina</name>
      <address>
        <city>Cecina</city>
        <zip>57023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Azienda USL 12 di Viareggio</name>
      <address>
        <city>Lido di Camaiore</city>
        <zip>55043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione Clinicizzata di Cardiologia - Az. Ospedaliera Maggiore della Carita</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - ASL 22</name>
      <address>
        <city>Novi Ligure</city>
        <zip>15067</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Azienda Ospedaliera Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Azienda USL 4</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Divisione di Cardiologia - Ospedale Maria Vittoria</name>
      <address>
        <city>Torino</city>
        <zip>10100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedalr di Verbania</name>
      <address>
        <city>Verbania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Proclemer A et al, Registro Italiano Pacemaker e Defibrillatori. Bollettino Periodico 2001. G Ital Aritmol Cardiostim 2002;5:5-31.</citation>
  </reference>
  <reference>
    <citation>Wittkampf FH, de Jongste MJ, Lie HI, Meijler FL. Effect of right ventricular pacing on ventricular rhythm during atrial fibrillation. J Am Coll Cardiol. 1988 Mar;11(3):539-45. Review.</citation>
    <PMID>2449483</PMID>
  </reference>
  <reference>
    <citation>Lau CP, Jiang ZY, Tang MO. Efficacy of ventricular rate stabilization by right ventricular pacing during atrial fibrillation. Pacing Clin Electrophysiol. 1998 Mar;21(3):542-8.</citation>
    <PMID>9558685</PMID>
  </reference>
  <reference>
    <citation>Mazzocca G, Giovannini T, Frascarelli F, Fabiani A, Burali A, Giappichini G, Bidi G, Bernabò D, Manfredini E, Corbucci G. Heart rate regularisation in patients with permanent atrial fibrillation implanted with a VVI(R) pacemaker. Europace. 2004 May;6(3):236-42.</citation>
    <PMID>15121077</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2005</study_first_submitted>
  <study_first_submitted_qc>October 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2005</study_first_posted>
  <results_first_submitted>November 6, 2009</results_first_submitted>
  <results_first_submitted_qc>August 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 28, 2011</results_first_posted>
  <last_update_submitted>August 23, 2011</last_update_submitted>
  <last_update_submitted_qc>August 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Permanent atrial fibrillation</keyword>
  <keyword>VVI(R) pacing</keyword>
  <keyword>rate regularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>enrollment period: from january 2006 till november 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>VRS ON</title>
          <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
        </group>
        <group group_id="P2">
          <title>VRS OFF</title>
          <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VRS ON</title>
          <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
        </group>
        <group group_id="B2">
          <title>VRS OFF</title>
          <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="6"/>
                    <measurement group_id="B2" value="80" spread="6"/>
                    <measurement group_id="B3" value="80" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Rate Irregularity Indicators and Patient's Symptoms</title>
        <time_frame>January 2009</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Should Undergo Atrioventricular Nodal (AVN) Ablation</title>
        <time_frame>January 2009</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Should Undergo Drug Therapy in Combination With Pacing to Stabilize Heart Rate</title>
        <time_frame>January 2009</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Potential Discomforts of Pacing Algorithm for Heart Rate Stabilization</title>
        <time_frame>January 2009</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE)</title>
        <description>Evaluation of patient preference concerning the programming of a specific algorithm for automatic Ventricular Rate Stabilization (VRS): Algorithm ON vs. OFF.</description>
        <time_frame>June 2009</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VRS ON</title>
            <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
          </group>
          <group group_id="O2">
            <title>VRS OFF</title>
            <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Mode Preference (VRS ON, VRS OFF, NO PREFERENCE)</title>
          <description>Evaluation of patient preference concerning the programming of a specific algorithm for automatic Ventricular Rate Stabilization (VRS): Algorithm ON vs. OFF.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preference VRS ON</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preference VRS OFF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Preference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>VRS ON vs. VRS OFF</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Z-test for proportions</method>
            <param_type>Proportions</param_type>
            <param_value>48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>36</ci_lower_limit>
            <ci_upper_limit>61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>VRS ON</title>
          <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
        </group>
        <group group_id="E2">
          <title>VRS OFF</title>
          <description>Ventricular Rate Stabilization is a programmed function of the implanted pacemaker. After the first phase (VRS ON or OFF) patients cross-over for the second phase (VRS OFF or ON)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HOSPITALIZATION FOR HF</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HOSPITALIZATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>should INVESTIGATOR contemplate publishing/presenting, he shall provide copies of any abstracts, papers, or manuscripts to sponsor for review at least 30 days prior to submittal for publication or presentation. Sponsor shall limit its review to a determination of whether Confidential Information is disclosed and to check for technical correctness and shall not attempt to censor or in any way interfere with PARTICIPATING INSTITUTION’s or INVESTIGATOR’s presentation or conclusions</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Giorgio Corbucci - Sr Principal Scientist</name_or_title>
      <organization>Medtronic BRC - Medtronic Italia</organization>
      <phone>+39 02 241371</phone>
      <email>giovanna.zucchi@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

